Safety and efficacy of novel oral anticoagulants: a comparison to vitamin K antagonists

Cardiovasc Hematol Agents Med Chem. 2014;12(1):9-13. doi: 10.2174/187152571201141201092129.

Abstract

Novel oral anticoagulants (NOACs) have been developed as alternatives for vitamin K antagonists (VKAs) for the prevention of thromboembolic events in patients with a variety of medical conditions. In this review, we summarize the current data on NOACs safety and efficacy compared to VKAs and in specific patients' groups including heart valve replacement, venous thromboembolism, advanced renal failure and the elderly.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants / standards*
  • Anticoagulants / therapeutic use*
  • Chemistry, Pharmaceutical / standards
  • Chemistry, Pharmaceutical / trends
  • Humans
  • Pulmonary Embolism / drug therapy
  • Renal Insufficiency / drug therapy
  • Renal Insufficiency / prevention & control
  • Thromboembolism / drug therapy*
  • Thromboembolism / prevention & control
  • Vitamin K / antagonists & inhibitors*

Substances

  • Anticoagulants
  • Vitamin K